Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof
AssigneeBioartic Neuroscience AB
InventorsPär Gellerfors, Lars Lannfelt
Life of this patent
Estimating the term…
Loading patent…
AssigneeBioartic Neuroscience AB
InventorsPär Gellerfors, Lars Lannfelt
Estimating the term…
The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.
An antibody specific for soluble amyloid beta peptide (Aβ) protofibrils and/or biologically active fragments thereof.
A method of synthesizing pure Aβ42arc protofibril antigen, comprising the steps of:
A method to synthesize pure wild type Aβ42 protofibril antigen, comprising the steps of:
A method of stabilizing Aβ protofibrils by mixing them with an agent that decreases the solvent polarity or one that lowers the surface tension, or a combination of said agents, and/or keeping the protofibrils at a temperature below 20° C.
Dependencies are inferred from the claim text.